Claims:

1. Use of an antibody which binds to CLDN18.2 for the preparation of a medicament for use in a method of treating or preventing a cancer disease characterized by expression CLDN18.2, said method comprising an antibody to be administered to a patient, said antibody having the ability of binding to CLDN18.2 in combination with an agent capable of increasing or stabilizing the expression of CLDN18.2,

wherein the antibody which binds to CLDN18.2 is capable of mediating killing of cells expressing CLDN18.2 by antibody dependent cellular cytotoxicity (ADCC) mediated lysis, wherein the antibody comprises an antibody heavy chain comprising the amino acid sequence represented by SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence represented by SEQ ID NO: 39; and

wherein the agent increasing or stabilizing the expression of CLDN18.2 is an agent selected from the group consisting of (i) oxaliplatin and 5-fluorouracil, (ii) epirubicin, oxaliplatin and 5-fluorouracil, (iii) 5-fluorouracil, folinic acid and oxaliplatin, (iv) Irinotecan, (v) Docetaxel, (vi) Epirubicin, (vii), Oxaliplatin, and (viii) Cisplatin, and prodrugs of said agents.

2. The use of claim 1, wherein the treatment comprises an agent stimulating γδ T cells to be administered.

3. The use of claim 2, wherein the agent stimulating γδ T cells is a nitrogen-containing bisphosphonate (aminobisphosphonate).

4. The use of claims 2 or 3, wherein the agent stimulating γδ T cells is selected from the group consisting of zoledronic acid, clodronic acid, ibandronic acid, pamidronic acid, risedronic acid, minodronic acid, olpadronic acid, alendronic acid, incadronic acid and salts thereof.

5. The use of any one of claims 1 to 4, wherein the method further comprises interleukin-2 to be administered.

6. The use of claim 5, wherein expression of CLDN18.2 is at the cell surface of a cancer cell.

7. The use of any one of claims 1 to 6, wherein the method comprises the antibody having the ability of binding to CLDN18.2 to be administered at a dose of up to 1000 mg/m^2.

8. The use of any one of claims 1 to 7, wherein the method comprises the antibody having the ability of binding to CLDN18.2 to be administered repeatedly at a dose of 300 to 600 mg/m^2.

9. The use of any one of claims 1 to 8, wherein the cancer is an adenocarcinoma, in particular an advanced adenocarcinoma.

10. The use of any one of claims 1 to 9, wherein the cancer is selected from the group consisting of cancer of the stomach, cancer of the esophagus, in particular the lower esophagus, cancer of the eso-gastric junction and gastroesophageal cancer.

11. The use of any one of claims 1 to 10, wherein the patient is a HER2/neu negative patient or a patient with HER2/neu positive status but not eligible to trastuzumab therapy.

12. The use of any one of claims 1 to 11, wherein CLDN18.2 has the amino acid sequence according to SEQ ID NO: 1.